Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 1 of 26
Safe and Explainable AI
Abramson Cancer Center at Penn Medicine
NCT06694181
Susan G. Komen's ShareForCures
Susan G. Komen Breast Cancer Foundation
NCT05654246
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
University of California, San Francisco
NCT02620852
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Agendia
NCT03053193
Rutgers University Study of the Genetics of Breast Cancer.
Rutgers, The State University of New Jersey
NCT06773897
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
UCF MammoChat: Image Repository
University of Central Florida
NCT07214883
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
UNC Lineberger Comprehensive Cancer Center
NCT01000883
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
Northwestern University
NCT00898131
UNC Pleural Fluid Registry
UNC Lineberger Comprehensive Cancer Center
NCT05620329
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
UMC Utrecht
NCT04075305
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Adela
NCT05366881
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
NCT01042379
Global Cardio Oncology Registry
The Cleveland Clinic
NCT05598879
Genomic Services Research Program
National Human Genome Research Institute (NHGRI)
NCT02595957
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Stemline Therapeutics
NCT06492616
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT00899301
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NRG Oncology
NCT05879926
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
UNC Lineberger Comprehensive Cancer Center
NCT07214610
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Stanford University
NCT01034033
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Emory University
NCT06760507
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
Carol Fabian, MD
NCT00291096
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
ARTIDIS
NCT06085833
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
University of Utah
NCT07029490
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group
NCT03488693
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
Margarita Louise Zuley
NCT05206331
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
American College of Radiology
NCT05625659
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
Memorial Sloan Kettering Cancer Center
NCT07308717
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Exact Sciences Corporation
NCT06401421
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
The New York Proton Center
NCT05313191
Collection of Blood From Patients With Cancer
National Cancer Institute (NCI)
NCT00034216
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Memorial Sloan Kettering Cancer Center
NCT06954337
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
University of Kansas Medical Center
NCT02302742
Biennial CEM in Women With a Personal History of Breast Cancer
Wendie Berg
NCT06105749
African Cancer Genome: GMD
Fox Chase Cancer Center
NCT05754658
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
University of Utah
NCT06305312
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Breast Cancer Trials, Australia and New Zealand
NCT06445738
EXoPERT EMERALD Clinical Study
EXoPERT
NCT07186296
Lymphedema Surveillance Study
Memorial Sloan Kettering Cancer Center
NCT02743858
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
SpotitEarly
NCT07038785
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Cancer Institute (NCI)
NCT01441089
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
University Hospital, Basel, Switzerland
NCT07140172
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Pfizer
NCT06760637
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
Identifying Patterns in the Breath of Individuals With Breast Cancer
Breathe BioMedical
NCT06512350
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
M.D. Anderson Cancer Center
NCT06127797
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
M.D. Anderson Cancer Center
NCT05694559
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
NCT05649072
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT07085767
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.